USNA Stock Recent News

Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?

STNE, CVS, KT, KB and USNA stand out in August for low P/B ratios and strong growth forecasts, making them value stock contenders.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

SALT LAKE CITY , Aug. 4, 2025 /PRNewswire/ -- With August marking National Wellness Month, Kevin Guest, Executive Chairman of USANA Health Sciences (NYSE: USNA), is encouraging people to embrace small daily habits that lead to lasting wellness mentally, physically, and emotionally. "Wellness isn't something you check off a list; it's a rhythm you live," said Guest, author of All the Right Reasons: 12 Timeless Principles for Living a Life in Harmony.

USANA Health (USNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?

USANA Health Sciences is resurfacing as an idea after a strong Q2 report. The direct selling business has continued to struggle with a decline in sales and active customers. A segment turnaround remains uncertain. The previous Hiya acquisition's potential is clearly showing. Operational expansion underlines massive long-term potential for USANA.

USANA Health Sciences, Inc. (NYSE:USNA ) Q2 2025 Earnings Conference Call July 23, 2025 11:00 AM ET Company Participants Andrew Masuda - Director of Investor Relations Brent L. Neidig - Chief Commercial Officer G.

USANA Health Sciences (USNA) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.54 per share a year ago.

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended June 28, 2025. Key Financial Results Second Quarter 2025 vs. Second Quarter 2024 Net sales of $236 million versus $213 million, representing 11% year-over-year growth. Net earnings of $9.7 million versus $10.4 million. Diluted EPS of $0.52 as compared with $0.54. Adjusted diluted EPS(1) of $0.74 as compared with $0.54. Adjusted EBITDA(2) of $30 million.